Oncolytic Virotherapy Europe Congress returns to London

Posted: 2 February 2017 | | No comments yet

The Oncolytic Virotherapy Europe Congress is the only conference in Europe dedicated specifically to the Oncolytic Virotherapy and converting research into the next generation of clinically-relevant virotherapeutics.

This year it will be held in London, and attendees will gain access to the very latest clinical progress and exclusive case studies. 

The conference is partnering up with some of the most innovative oncolytic virotherapy pioneers including Transgene, PsiOxus Therapeutic,  Lokon, Virttu, Oxford Genetics, Targovax, VCN Biosciences and many more.

Investment and interest in oncolytic virotherapy has gathered significant momentum in the industry since T-VEC (Talimogene laherparepvec) was granted approval. Research has shown how effective and efficient it can be, however significant challenges remain.

For more information, visit

Related topics

Related organisations